Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
Full story
Shanghai Zhimeng Biopharma has finished enrolling patients for a clinical trial of its drug CB03-154. The medication is a next-generation potassium channel opener developed to treat amyotrophic lateral sclerosis. A total of 255 patients joined the pivotal Phase 2/3 trial. The company developed the drug independently.
SHANGHAI, Oct. 31, 2026 /PRNewswire/ — Shanghai Zhimeng Biopharma, Inc. ( “Zhimeng Biopharma”) announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully completed patient enrollment in its pivotal Phase 2/3 clinical trial, in total enrolled 255 patients. This significant milestone marks the entry […]